local_hospital

University Hospitals Pitie Salpetriere Charles Foix

Address
47 To 83 Boulevard De L Hopital, 75013 Paris, France

Oncology and Hematologic Malignancies

At University Hospitals Pitie Salpetriere Charles Foix, the Medical Oncology program is strongly focused on neoplasms, with trials exploring new ways to treat acute myeloid leukaemia, multiple myeloma, follicular lymphoma, diffuse large B-cell lymphoma, and metastatic breast cancer. These studies are designed to test more effective cancer therapies, compare treatment options, and improve outcomes for patients with advanced or relapsed disease.

  • Testing new treatment strategies for acute myeloid leukaemia and multiple myeloma
  • Evaluating therapies for lymphoma and other blood cancers
  • Assessing novel approaches for breast cancer and other advanced solid tumors

This research also includes studies aimed at improving disease control after prior treatment, helping define better options for patients with hard-to-treat cancers.

Cardiovascular and Metabolic Research

The site is active in cardiovascular diseases and nutritional and metabolic diseases, with trials in atherosclerotic cardiovascular disease, non-obstructive coronary artery disease, STEMI, and severe hypertriglyceridemia. Research here focuses on preventing heart events, reducing plaque burden, and improving blood lipid control through better therapies.

  • Studying treatments for atherosclerotic cardiovascular disease and coronary artery disease
  • Evaluating emergency care approaches for acute heart attack
  • Testing therapies to lower triglycerides and reduce metabolic risk

These trials aim to improve long-term cardiovascular health and support earlier, more effective intervention in high-risk patients.

Liver, Digestive, and Viral Disease Studies

Clinical trials at this Paris site also cover digestive system diseases and virus diseases, including chronic hepatitis D infection, non-alcoholic steatohepatitis, locoregional hepatocellular carcinoma, and squamous carcinoma of the anal canal. The main goal is to evaluate treatments that may slow liver damage, control cancer growth, and improve disease-related symptoms.

  • Investigating therapies for chronic liver disease and hepatitis D
  • Assessing treatment options for NASH and hepatocellular carcinoma
  • Exploring new approaches for anal cancer and related digestive cancers

Several studies are designed to measure whether these treatments can better protect liver function and delay disease progression.

Neurology and Alzheimer’s Disease Research

The research portfolio includes nervous system diseases, with studies in Alzheimer’s disease and seizure disorders. These trials are focused on improving symptom control, slowing cognitive decline, and finding more effective options for patients living with progressive neurological conditions.

  • Evaluating treatments for early Alzheimer’s disease and prodromal cognitive decline
  • Studying medicines that may help preserve memory and function
  • Assessing therapies for seizure episodes and rapid symptom relief

This area reflects a broader effort to improve both daily functioning and long-term outcomes in neurological illness.

Immune, Rheumatology, and Transplant-Related Conditions

Trials in immune system diseases and musculoskeletal diseases include psoriatic arthritis, rheumatoid arthritis, and high-risk acute graft versus host disease. The research is centered on finding safer and more effective ways to control inflammation, reduce immune-related complications, and improve quality of life.

  • Testing therapies for psoriatic arthritis and rheumatoid arthritis
  • Evaluating treatment options for acute graft versus host disease
  • Exploring better control of immune-mediated inflammation

These studies support ongoing progress in managing chronic inflammatory disease and complex post-transplant immune problems.

Respiratory and Infectious Disease Research

The site also participates in trials for respiratory tract diseases and virus diseases, including nontuberculous mycobacterial lung infection and other chronic lung infections. The purpose of this research is to improve respiratory symptom relief, infection control, and overall lung health in patients with difficult-to-treat disease.

  • Studying treatment approaches for NTM lung infection
  • Assessing ways to improve respiratory symptoms and infection outcomes
  • Supporting better care for patients with persistent lung disease

This work adds important insight into managing infections that often require long-term and specialized treatment.

Rare Diseases, Genetic Conditions, and Neuromuscular Disorders

Research at University Hospitals Pitie Salpetriere Charles Foix extends to congenital, hereditary, and neonatal diseases and abnormalities, with trials in FKRP-related limb-girdle muscular dystrophy and other rare inherited conditions. These studies are intended to assess new therapies that may improve muscle function, disease stability, and patient independence.

  • Evaluating treatment options for limb-girdle muscular dystrophy
  • Studying therapies for genetic muscle disease
  • Exploring approaches that may support mobility and daily function

The focus on rare disease research highlights the center’s role in advancing care where treatment options are often limited.

Site Overview

assignment
74
connected trials
corporate_fare
55
sponsors
science
193
IMPs

Activity Indicator

Last 6 months

1
Trials started
0% vs previous period.
1
Trials started 6–12 months ago
74
Total trials linked
Highly Active
trending_flatStable0%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 21 therapeutic areas and 15 of 193 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 184 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
28
Sponsors (total)
55
Active sponsors
23

Sponsor Network

Top 23 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +13 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
74
Outperforms 91% of sites
public
Therapeutic diversity
21areas
Outperforms 95% of sites
groups
Sponsor diversity
55sponsors
Outperforms 93% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in University Hospitals Pitie Salpetriere Charles Foix

lock Showing 1 of 74 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host DiseaseCynata Therapeutics LimitedPhase IINot RecruitingJul 2024Jun 2026

IMP list

lock Showing 1 of 193 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Florbetaben (18F)4Unknown2021-10-182024-05-07

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.